2 citations
,
March 2020 in “Baghdad Science Journal” This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.
June 2019 in “Journal of Drug Delivery and Therapeutics” This review highlights the use of finasteride, a 5alpha-reductase inhibitor, for treating benign prostatic hyperplasia and male pattern hair loss, noting that it may cause male sexual dysfunction but usually with tolerable side effects that decrease over time, not requiring treatment discontinuation.
3 citations
,
April 2019 in “Human & Experimental Toxicology” This study found that finasteride caused adverse effects on liver, kidney, and heart tissues in female mice, raising concerns about its potential use in females for treating androgenetic alopecia.
April 2013 in “e-Jurnal Medika Udayana” This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.
6 citations
,
November 2010 in “International Journal of Andrology” In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.
9 citations
,
January 2009 in “PubMed” This study found that finasteride treatment in men with benign prostate hyperplasia significantly altered steroid hormone profiles and may contribute to depressive symptoms by affecting neuroactive steroid levels.
This study suggests that the negative impact of high-dose Finasteride on male reproductive function may be mitigated by concurrent administration with TU.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.
113 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.
3 citations
,
June 1996 in “PubMed” This review discusses the effects and potential benefits of finasteride in treating hirsutism and androgenetic alopecia but reports no new clinical results.
93 citations
,
January 1996 in “Clinical Pharmacokinectics” Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
73 citations
,
January 1994 in “European Urology” This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.
34 citations
,
July 1993 in “PubMed” This article reviews the characteristics and uses of finasteride for benign prostatic hyperplasia, noting variable symptom improvement and ongoing investigation in other DHT-mediated conditions, and reports no new clinical results.
34 citations
,
February 1992 in “The Journal of Clinical Endocrinology and Metabolism” In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.
